Key facts
- Auron Therapeutics’s last known valuation is $106.3M (Dec 2025).
- It has raised $90.7M across 4 recorded rounds; the latest was Early Stage VC ($27.3M) in Dec 2024.
- Notable investors include Qiming Venture Partners USA, DCVC, Polaris Partners, Arkin Capital, Casdin Capital — 15 tracked in total.
- Auron Therapeutics has filed 5 Form Ds with the SEC since 2018, most recently Dec 2024 ($13.4M sold to 15 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Auron Therapeutics
Funding rounds
4 roundsAbout Auron Therapeutics
Operator of a biotechnology company intended to research and develop products focusing on the immunology and oncology medical fields. The company's research aims to cure cancer by changing the paradigm of cancer therapeutics from cell killing to the transformation of malignant cells into normal functioning cells, enabling researchers to focus on the advancement of novel drugs in areas of unmet medical need and offer life-saving, transformative medicines for cancer patients.
- Sector
- Healthcare
- HQ
- Newton, MA, United States
- Founded
- 2018
- Employees
- 23
- Website
- aurontx.com/
- Ownership
- Privately Held (backing)
Auron Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Auron Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Auron Therapeutics in its N-PORT filings yet. We sweep new filings monthly.